Ignite Creation Date:
2025-12-25 @ 4:47 AM
Ignite Modification Date:
2026-03-08 @ 3:35 AM
Study NCT ID:
NCT02452918
Status:
COMPLETED
Last Update Posted:
2023-12-20
First Post:
2015-05-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Sponsor:
The Medicines Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-09-29
Start Date Type:
ACTUAL
Primary Completion Date:
2016-07-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-07-05
Completion Date Type:
ACTUAL
First Submit Date:
2015-05-13
First Submit QC Date:
None
Study First Post Date:
2015-05-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-11-08
Results First Submit QC Date:
None
Results First Post Date:
2023-12-20
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-18
Last Update Post Date:
2023-12-20
Last Update Post Date Type:
ACTUAL